Personalized Follow-up Treatment After Stomach Cancer Surgery
Part of Cancer, Digestive system clinical trials.
This study tests whether giving personalized follow-up treatment after stomach cancer surgery and chemotherapy can help prevent the cancer from coming back. The treatment plan is tailored based on how well the tumor responded to initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your stomach or part of your stomach and esophagus for adenocarcinoma (a type of cancer), with complete removal of the tumor
- You received chemotherapy combined with immunotherapy (drugs that boost your immune system) before your surgery
- Your cancer falls into one of two specific categories based on how it responded to chemotherapy and what was found during surgery
- You are between 18 and 75 years old and in good enough health to tolerate treatment (ECOG score 0 or 1)
- You have no signs of cancer spread to other parts of your body on imaging scans after surgery
- Your blood work and organ function (liver, kidneys, thyroid) are within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
This trial compares two approaches after surgery for early-stage stomach or GEJ cancer: close monitoring (follow-up) vs. adjuvant chemotherapy (chemo given after surgery). It aims to see if follow-up alone is as good as chemo for patients with this stage, potentially avoiding chemo side effects.
This trial is for people who have already had chemotherapy and surgery for stomach cancer. It compares different follow-up approaches to see if skipping more chemo after surgery is safe and effective.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.